Age (year) | median (min-max) | 61 (33–84) |
---|---|---|
Gender (n, %) | Male | 109 (64.5%) |
Female (n, %) | 60 (35.5%) | |
Side (n, %) | Right (n, %) | 84 (49.7%) |
Left (n, %) | 85 (50.3%) | |
Body Mass Index (kg/m2) | mean ± SD | 29.00 ± 4.28 |
Tumour Size (cm) | median (min-max) | 6.5 (2–18) |
Tumour Localisation (n, %) | Lower Pole | 26 (15.4%) |
Middle Pole | 97 (57.4%) | |
Upper Pole | 46 (27.2%) | |
Tumour Type (n, %) | Clear Cell | 114 (67.5%) |
Chromophobe Cell | 16 (9.5%) | |
Papillary | 15 (8.9%) | |
Angiomyolipoma | 11 (6.5%) | |
Oncocytoma | 13 (7.7%) | |
Malignancy (n, %) | Malign | 145 (85.8%) |
Benign | 24 (14.2%) | |
Fuhrman Grade (n, %) | Grade 2 | 43 (33.3%) |
Grade 3 | 71 (55.0%) | |
Grade 4 | 15 (11.6%) | |
Tumour Stage (n, %) | T1a | 24 (16.7%) |
T1b | 36 (25.0%) | |
T2a | 16 (11.1%) | |
T2b | 6 (4.2%) | |
T3a | 46 (31.9%) | |
T3b | 11 (7.6%) | |
T4 | 5 (3.5%) | |
Smoking Status (n, %) | Exist | 116 (68.6%) |
None | 53 (31.4%) | |
Diabetes Mellitus (n, %) | Exist | 67 (39.6%) |
None | 102 (60.4%) | |
Hypertension (n, %) | Exist | 105 (62.1%) |
None | 64 (37.9%) | |
Triglyceride Value [mg/dl] | median (min-max) | 145 (68–1019) |
HDL-Cholesterol Value [mg/dl] | mean ± SD | 41.12 ± 11.94 |
Plasma Atherogenic Index Value | median (min-max) | 0.53 (0.15–1.58) |